Justification for Atherosclerosis Regression Treatment [JART Extension Study]

Trial Profile

Justification for Atherosclerosis Regression Treatment [JART Extension Study]

Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2016

At a glance

  • Drugs Rosuvastatin (Primary) ; Pravastatin
  • Indications Atherosclerosis; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms JART
  • Most Recent Events

    • 29 Aug 2012 Results of an analysis of the extension study (n=118) presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 16 Nov 2011 Results published in Circulation Journal.
    • 31 Aug 2011 Actual patient number (n=295) reported in an abstract presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top